SUMMARY We diagnosed non X-linked hypophosphataemic bone disease in a 38-month-old girl. Findings included: genu varum, shortened stature, fasting hypophosphataemia (2 3-2 5 mg/100 ml; 0 74-0481 mmol/l), diminished theoretical renal threshold for phosphate (TmP/GFR), and osteomalacia without rickets. One parent (the father) had fasting hypophosphataemia (2-3-2-7 mg/100 ml; 0 74J-087 mmol/l) and low TmP/GFR without osteomalacia or shortened stature. Treatment of the girl with 1,25-(OH)2D3 (1 Ftg a day) raised the level of serum phosphorus, improved tubular reabsorption of phosphate, and healed the bone deformity; this combination of responses is not present in X-linked hypophosphataemia. There was no correction of hypophosphataemia or TmP/ GFR with 1,25-(OH)2D3 treatment (1-3 ,ug a day) in the father.
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Hypophosphataemic bone disease (HBD)1 is an inherited disorder of phosphate homeostasis. Although the condition is in some ways analogous to X-linked hypophosphataemia (XLH),2 there are important differences between the two diseases. HBD is an autosomal disorder, dominant in its inheritance when not sporadic whereas XLH, also dominantly inherited, is the product of mutation at a locus on the X-chromosome. While in both conditions there is osteomalacia of endosteal trabecular bone, only in XLH is florid rickets present, affecting the epiphyses and compromising linear growth. In both diseases there is a reduced theoretical renal threshold for phosphate (TmP/ GFR) and an impaired maximum tubular reabsorption activity for phosphate (TmP). Fractional renal excretion of filtered phosphate is normal in the fasting hypophosphataemic state in HBD, whereas it is greatly increased at the equivalent serum phosphate level in XLH: and while residual phosphate reabsorption activity is readily inhibited by parathyroid hormone in HBD, it is insensitive to the hormone in XLH. Thus, HBD differs from XLH, both in bone metabolism and in renal handling of phosphate, despite comparable hypophosphataemia in each. The There were no clinical signs of rickets and dental development was normal. Her weight was at the 10th centile, and standing height just below the 3rd (Stuart-Meredith growth charts). Intestinal malabsorption was excluded on clinical evidence and by the appropriate laboratory investigations and so, too, were hepatic and renal disease. Roentgen-ray examination showed no rachitic bone changes; however, there was coarsened trabeculation in metaphyses and diaphyses of long bones and sclerosis in the distal medial metaphyses of both femora, as reported in previous patients.1 Additional investigation showed: serum total calcium 9 5 mg/100 ml (2-4 mmol/l), serum phosphorus 2-5 mg/100 ml (0-81 mmol/l), serum alkaline phosphatase 221 SIU. Urine contained an increased amount of glycine (discerned by 2-dimensional partition chromatography of amino-acids).3 A similar finding in each parent implied that the daughter was probably a heterozygote for the mutation causing renal iminoglycinuria, a benign inborn error of amino-acid transport. 4 Special investigations. Additional studies in the patient showed: normal serum level of immunoreactive parathyroid hormone (measured in the laboratory of FH Glorieux using a modified Cterminal antiserum for radioimmune assay by the method of Arnaud et Family studies. Fasting serum samples were obtained from both parents and from a 4i-year-old brother, and levels of serum calcium, phosphorus, and alkaline phosphatase were measured. Linear height and body weight were measured too. The results (Table 1) showed that the father had hypophosphataemia, his average fasting serum phosphorus concentration being below the 99 % confidence limit for age-specific normal values in males. 7 The mother and brother were normal. Stature and body proportions of the father were normal and no abnormality of bone mineralisation could be detected by roentgen-ray examination. Trephine biopsy of his right iliac crest showed normal endosteal trabecular morphology bone despite his chronic hypophosphataemia.* Renal handling of phosphate. Tubular reabsorption of phosphate (TRP) and TmP/GFR were estimated in the patient and in her father and mother at a time when their daily dietary intakes of phosphorus and calcium were normal and constant. TRP was measured by methods described previously,1 TmP/GFR from the nomogram of Walton and Bijvoet.8
Absolute TRP (,tatom/100 ml GF) was below normal in both hypophosphataemic subjects ( Fig. 1 and Table 2 ) as, in both the girl and her father, the filtered phosphate was below the normal range. However, the average fractional reabsorption (expressed as % TRP) was normal ( Table 2) . TmP/ GFR, in the patient, was below the range of values characteristic in children; the father had a low normal value. The mother, who did not have hypophosphataemia, had normal renal handling of phosphate.
The tubular response to a rapid intravenous infusion ofparathyroid gland extract (Para-thormone Lilly) was studied by the method reported previously.9 Urinary cyclic-AMP excretion increased 10-fold from a normal baseline (8 35 nmol/mg creatinine) in the initial 30-minute period after the parathyroid gland infusion; this response is within the normal range.10 At the same time fractional excretion of phosphate increased 4-7-fold; this response is quite different from the blunted phosphate excretion response characteristic of XLH9 and probably is greater than the normal response (D E C Cole and C R Scriver, unpublished data). there would be a rise after the dosage had been increased and a fall after the drug had been reduced or stopped (Fig. 2) . On one occasion during the first cycle of treatment serum phosphorus fell spontaneously to below the normal range, without change in dosage.
Height increased to the 3rd centile in the patient and height velocity changed from the 50th to the 90th centile (Tanner chart). Roentgen-ray studies indicated steady improvement of bone mineralisation, but bone biopsies were not performed. We are confident that our patient has a Mendelian form of hypophosphataemia that is not XLH. The reason for our confidence in this diagnosis is that the HBD and XLH phenotypes are different; in our experience the HBD phenotype is consistently expressed in children, and our patient resembles others; father-to-son transmission of the HBD phenotype has been observed, thus eliminating X-linkage of the HBD gene.
New findings in HBD, since the original description, and gained largely from the present study, are:
(1) normal serum 1,25-(OH)2D3 levels in this and in other HBD patients;13 (2) a rise in the serum level of phosphorus related to enhanced renal reabsorption after treatment with 1,25-{OH)2D3; (3) improved bone mineralisation during prolonged treatment with 1,25-(OH)2D3; (4) The investigation also provided useful information for the clinician: it showed that HBD in childhood could be successfully treated with 1,25-{OH)2D3.
In XLH, the other main form of 'phosphopenic' bone disease in childhood," the hypophosphopenia responds poorly to 1,25-(OH)2D3 in older patients14-'5 and modestly in children under longterm treatment, it is not associated with any change in TmP/GFR (T Costa, T M Reade, D E C Cole, and C R Scriver, unpublished data). However, treatment with the drug in combination with phosphate replacement greatly improves bone mineralisation in XLH (F H Glorieux, personal communication; T Costa et al., 1980, unpublished data). Thus, the clinical management and prevention of limb deformity in HBD should be a fairly simple matter in the future, provided there is careful supervision of the patient to prevent hypercalcaemia (Fig. 2) .
Different mechanisms for tubular reabsorption of phosphate anion seem to be affected in XLH and HBD.1 Evidence from these two diseases indicates that the human nephron may possess one mechanism, more sensitive to inhibition by parathyroid hormone, which is under the control of an X-linked gene, and another less sensitive to parathyroid hormone which is under the control of an autosomal gene. Recent studies [16] [17] [18] [19] 
